Literature DB >> 29133208

Homozygous loss of function BRCA1 variant causing a Fanconi-anemia-like phenotype, a clinical report and review of previous patients.

Bruna L Freire1, Thais K Homma1, Mariana F A Funari2, Antônio M Lerario3, Aline M Leal4, Elvira D R P Velloso4, Alexsandra C Malaquias5, Alexander A L Jorge6.   

Abstract

BACKGROUND: Fanconi Anemia (FA) is a rare and heterogeneous genetic syndrome. It is associated with short stature, bone marrow failure, high predisposition to cancer, microcephaly and congenital malformation. Many genes have been associated with FA. Previously, two adult patients with biallelic pathogenic variant in Breast Cancer 1 gene (BRCA1) had been identified in Fanconi Anemia-like condition. CLINICAL REPORT: The proband was a 2.5 year-old girl with severe short stature, microcephaly, neurodevelopmental delay, congenital heart disease and dysmorphic features. Her parents were third degree cousins. Routine screening tests for short stature was normal.
METHODS: We conducted whole exome sequencing (WES) of the proband and used an analysis pipeline to identify rare nonsynonymous genetic variants that cause short stature.
RESULTS: We identified a homozygous loss-of-function BRCA1 mutation (c.2709T > A; p. Cys903*), which promotes the loss of critical domains of the protein. Cytogenetic study with DEB showed an increased chromosomal breakage. We screened heterozygous parents of the index case for cancer and we detected, in her mother, a metastatic adenocarcinoma in an axillar lymph node with probable primary site in the breast.
CONCLUSION: It is possible to consolidate the FA-like phenotype associated with biallelic loss-of-function BRCA1, characterized by microcephaly, short stature, developmental delay, dysmorphic face features and cancer predisposition. In our case, the WES allowed to establish the genetic cause of short stature in the context of a chromosome instability syndrome. An identification of BRCA1 mutations in our patient allowed precise genetic counseling and also triggered cancer screening for the patient and her family members.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  BRCA1; FANC genes; FANCA genes; Fanconi anemia; Genomic instability

Mesh:

Substances:

Year:  2017        PMID: 29133208     DOI: 10.1016/j.ejmg.2017.11.003

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  17 in total

Review 1.  Impact of DNA repair and stability defects on cortical development.

Authors:  Federico T Bianchi; Gaia E Berto; Ferdinando Di Cunto
Journal:  Cell Mol Life Sci       Date:  2018-08-16       Impact factor: 9.261

2.  Evidence of Intertissue Differences in the DNA Damage Response and the Pro-oncogenic Role of NF-κB in Mice with Disengaged BRCA1-PALB2 Interaction.

Authors:  Amar Hekmat Mahdi; Yanying Huo; Yongmei Tan; Srilatha Simhadri; Gabriele Vincelli; Jie Gao; Shridar Ganesan; Bing Xia
Journal:  Cancer Res       Date:  2018-05-08       Impact factor: 12.701

Review 3.  New developments in the genetic diagnosis of short stature.

Authors:  Youn Hee Jee; Jeffrey Baron; Ola Nilsson
Journal:  Curr Opin Pediatr       Date:  2018-08       Impact factor: 2.856

4.  Novel FANCA mutation in the first fully-diagnosed patient with Fanconi anemia in Polish population - case report.

Authors:  Anna Repczynska; Agata Pastorczak; Katarzyna Babol-Pokora; Jolanta Skalska-Sadowska; Malgorzata Drozniewska; Wojciech Mlynarski; Olga Haus
Journal:  Mol Cytogenet       Date:  2020-08-10       Impact factor: 2.009

5.  Mechanism for survival of homozygous nonsense mutations in the tumor suppressor gene BRCA1.

Authors:  Aaron Seo; Orna Steinberg-Shemer; Sule Unal; Silvia Casadei; Tom Walsh; Fatma Gumruk; Stavit Shalev; Akiko Shimamura; Nurten Ayse Akarsu; Hannah Tamary; Mary-Claire King
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-30       Impact factor: 11.205

6.  Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.

Authors:  Katharina Keupp; Stephanie Hampp; Annette Hübbel; Monika Maringa; Sarah Kostezka; Kerstin Rhiem; Anke Waha; Barbara Wappenschmidt; Roser Pujol; Jordi Surrallés; Rita K Schmutzler; Lisa Wiesmüller; Eric Hahnen
Journal:  Mol Genet Genomic Med       Date:  2019-07-25       Impact factor: 2.183

7.  Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era.

Authors:  Gabriel S Macedo; Barbara Alemar; Patricia Ashton-Prolla
Journal:  Genet Mol Biol       Date:  2019-04-29       Impact factor: 1.771

8.  The BRCA1 c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic BRCA1 Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability.

Authors:  Adalgeir Arason; Bjarni A Agnarsson; Gudrun Johannesdottir; Oskar Th Johannsson; Bylgja Hilmarsdottir; Inga Reynisdottir; Rosa B Barkardottir
Journal:  Genes (Basel)       Date:  2019-11-01       Impact factor: 4.096

9.  BRCA1 Mutational Complementation Induces Synthetic Viability.

Authors:  Joseph Nacson; Daniela Di Marcantonio; Yifan Wang; Andrea J Bernhardy; Emma Clausen; Xiang Hua; Kathy Q Cai; Esteban Martinez; Wanjuan Feng; Elsa Callén; Wei Wu; Gaorav P Gupta; Joseph R Testa; André Nussenzweig; Stephen M Sykes; Neil Johnson
Journal:  Mol Cell       Date:  2020-04-30       Impact factor: 17.970

Review 10.  Genetic Screening for Growth Hormone Therapy in Children Small for Gestational Age: So Much to Consider, Still Much to Discover.

Authors:  Claudio Giacomozzi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-28       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.